Zepbound (Tirzepatide) Significantly Lowers Systolic Blood Pressure: Study

Zepbound: The newest obesity medication explained by an expert | CNN
The new weight loss medication Zepbound (tirzepatide) significantly lowered systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in the journal Hypertension.In this study, tirzepatide’s impact on blood pressure reduction, during both the day and night, was impressive, says the lead study author, James A. de Lemos, MD, who serves as the chair of cardiology and a professor of medicine at UT Southwestern Medical Center in Dallas. Though studied as a weight loss drug, the blood pressure reduction achieved by tirzepatide is about what would be expected from a blood pressure lowering drug, says Dr. de Lemos.

Tirzepatide is sold as Mounjaro when prescribed for type 2 diabetes.

The efficacy of Zepbound in lowering blood pressure (also called hypertension) has important implications for treating obesity, says Michael E. Hall, MD, a volunteer expert with the American Heart Association (AHA), a cardiologist, and the chair of the school of medicine at the University of Mississippi Medical Center in Jackson.

“Hypertension is the most attributable risk factor for cardiovascular diseases, thus, effective treatments for common causes of hypertension such as obesity are needed. Effectively, this is treating the root cause of hypertension — obesity — rather than treating the secondary high blood pressure,” says Dr. Hall, who was not involved in the study.


Please enter your comment!
Please enter your name here

Stay in Touch

To follow the best weight loss journeys, success stories and inspirational interviews with the industry's top coaches and specialists. Start changing your life today!


Related Articles